Mai Capital Management Abb Vie Inc. Transaction History

Mai Capital Management

$10.1 Billion
Q3 2024

A detailed history of Mai Capital Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Mai Capital Management holds 358,313 shares of ABBV stock, worth $64.5 Million. This represents 0.7% of its overall portfolio holdings.

Number of Shares

358,313

Previous 373,085 3.96%

Holding current value

$64.5 Million

Previous $64 Million 10.58%

% of portfolio

0.7%

Previous 0.65%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$163.84 - $199.33 $2.42 Million - $2.94 Million	-14,772 Reduced 3.96%	358,313 $70.8 Million
Q2 2024 Aug 12, 2024	BUY	$154.79 - $180.76 $345,955 - $403,998	2,235 Added 0.6%	373,085 $64 Million
Q1 2024 May 08, 2024	BUY	$159.82 - $182.1 $3.87 Million - $4.41 Million	24,229 Added 6.99%	370,850 $67.5 Million
Q4 2023 Feb 09, 2024	BUY	$137.6 - $154.97 $305,196 - $343,723	2,218 Added 0.64%	346,621 $53.7 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $1.58 Million - $1.83 Million	11,807 Added 3.55%	344,403 $51.3 Million
Q2 2023 Aug 02, 2023	SELL	$132.51 - $164.9 $1.68 Million - $2.09 Million	-12,686 Reduced 3.67%	332,596 $44.8 Million
Q1 2023 May 10, 2023	SELL	$144.61 - $166.54 $196,235 - $225,994	-1,357 Reduced 0.39%	345,282 $55 Million
Q4 2022 Feb 09, 2023	BUY	$138.31 - $165.87 $1.75 Million - $2.09 Million	12,629 Added 3.78%	346,639 $56.1 Million
Q3 2022 Nov 15, 2022	BUY	$134.21 - $153.93 $4.53 Million - $5.19 Million	33,749 Added 11.24%	334,010 $44.8 Million
Q2 2022 Jul 19, 2022	BUY	$137.62 - $174.96 $266,845 - $339,247	1,939 Added 0.65%	300,261 $46 Million
Q1 2022 May 10, 2022	SELL	$131.98 - $163.75 $38.8 Million - $48.1 Million	-294,033 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$107.43 - $135.93 $6.97 Million - $8.81 Million	64,837 Added 28.29%	294,033 $39.8 Million
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $552,854 - $627,572	5,196 Added 2.32%	229,196 $24.7 Million
Q2 2021 Jul 19, 2021	SELL	$105.21 - $117.21 $2.16 Million - $2.41 Million	-20,535 Reduced 8.4%	224,000 $25.2 Million
Q1 2021 May 10, 2021	SELL	$102.3 - $112.62 $5.67 Million - $6.24 Million	-55,424 Reduced 18.48%	244,535 $26.5 Million
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $1.08 Million - $1.46 Million	13,479 Added 4.71%	299,959 $32.1 Million
Q3 2020 Oct 26, 2020	SELL	$85.91 - $100.83 $5.26 Million - $6.17 Million	-61,185 Reduced 17.6%	286,480 $25.1 Million
Q2 2020 Jul 27, 2020	BUY	$73.37 - $98.18 $19.2 Million - $25.7 Million	261,473 Added 303.36%	347,665 $34.1 Million
Q1 2020 Apr 16, 2020	SELL	$64.5 - $97.79 $361,264 - $547,721	-5,601 Reduced 6.1%	86,192 $6.57 Million
Q4 2019 Feb 03, 2020	BUY	$72.13 - $90.25 $2.23 Million - $2.8 Million	30,976 Added 50.93%	91,793 $8.13 Million
Q3 2019 Oct 29, 2019	BUY	$62.98 - $75.72 $33,001 - $39,677	524 Added 0.87%	60,817 $4.61 Million
Q2 2019 Aug 15, 2019	SELL	$65.7 - $83.98 $6,110 - $7,810	-93 Reduced 0.15%	60,293 $4.39 Million
Q1 2019 Apr 29, 2019	BUY	$77.14 - $90.79 $25,456 - $29,960	330 Added 0.55%	60,386 $4.87 Million
Q4 2018 Jan 30, 2019	BUY	$77.85 - $96.01 $666,473 - $821,941	8,561 Added 16.62%	60,056 $5.54 Million
Q3 2018 Oct 12, 2018	SELL	$88.91 - $98.84 $46,766 - $51,989	-526 Reduced 1.01%	51,495 $4.87 Million
Q2 2018 Aug 16, 2018	BUY	$89.78 - $106.23 $227,412 - $269,080	2,533 Added 5.12%	52,021 $4.82 Million
Q1 2018 Apr 17, 2018	BUY	$92.01 - $123.21 $420,761 - $563,439	4,573 Added 10.18%	49,488 $4.68 Million
Q4 2017 Jan 30, 2018	BUY	$89.56 - $98.21 $631,218 - $692,184	7,048 Added 18.61%	44,915 $4.34 Million
Q3 2017 Oct 12, 2017	BUY	$69.85 - $89.22 $139 - $178	2 Added 0.01%	37,867 $3.37 Million
Q2 2017 Aug 07, 2017	BUY	N/A	37,865	37,865 $2.75 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Mai Capital Management with notifications on news.

Account

Mai Capital Management Abb Vie Inc. Transaction History